Results 191 to 200 of about 25,638 (254)

Weight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-Analysis. [PDF]

Clin Obes
Lu D, Li N, Yuan Z, Gao Y.
europepmc   +1 more source

Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10418-10427, November 2026.
ABSTRACT Aims Compare healthcare cost trends among older adults with obesity or overweight treated with tirzepatide versus no treatment. Materials and Methods Retrospective cohort study using real‐world data from US Komodo Research Dataset, 8 November 2022 to 30 September 2025.
Navneet Upadhyay, Ali Bonakdar, Keshab Subedi, Soutrik Banerjee, Benjamin Behrend, Emily R. Hankosky   +5 more
wiley   +1 more source

GLP-1 Receptor Agonists in Epilepsy: Separating Evidence for Antiseizure Activity, Neuroprotection, and Disease Modification. [PDF]

Int J Mol Sci
Gorgul YA, Zaitsev AV.
europepmc   +1 more source

Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10780-10794, November 2026.
ABSTRACT Objective Treatment response in type 2 diabetes (T2D) varies widely among individuals. This study aimed to quantify the contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose‐lowering therapies.
S. Garg, R. Kitchen, R. Gupta, L. Donnelly, E. R. Pearson   +4 more
wiley   +1 more source

Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues. [PDF]

BMJ Open
Popa Ilie IR, Ghibu S, Butuca A, Dobrea CM, Frum A, Stoicescu L, Homorodean C, Gligor FG, Morgovan C.   +8 more
europepmc   +1 more source

Cardiorenal Mortality and Safety Outcomes of GLP‐1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10498-10512, November 2026.
ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen, Yu‐Nan Huang, Pei‐Yun Li, Jo‐Ching Chen, Gideon Meyerowitz‐Katz, Shun‐Fa Yang, Pen‐Hua Su   +6 more
wiley   +1 more source

Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications. [PDF]

J Diabetes Investig
Katamine A, Oya J, Kondo Y, Hasegawa Y, Nakagami T.   +4 more
europepmc   +1 more source

GLP‐1 Receptor Agonists Post‐Bariatric Surgery (GRABS) Trial: Rationale, Design and Baseline Characteristics

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9861-9870, November 2026.
ABSTRACT Aims No studies have investigated the synergistic effectiveness of Glucagon‐Like Peptide 1 Receptor Agonists (GLP1RAs) in patients with persistent obesity following bariatric surgery. The GLP‐1 Receptor Agonists Post‐Bariatric Surgery (GRABS) Trial aims to investigate the effectiveness of tirzepatide (TRZ) versus standard of care (SOC) after ...
J. M. Samuels, C. R. Williams, M. B. Patel, W. H. Self, L. M. Funk, C. Roumie, M. D. Spann, C. J. Northup, F. Ye, R. Irlmeier, I. Sohn, Y. Zhu, K. Niswender   +12 more
wiley   +1 more source

Adipose Tissue Remodeling Beyond Weight Loss: New Insights Into Incretin-Based Therapies and Bariatric Surgery. [PDF]

Curr Obes Rep
Abud GF, de Freitas EC, Stanford KI.
europepmc   +1 more source

SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

European Journal of Haematology, Volume 117, Issue 5, Page 1347-1357, November 2026.
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu, Anna Sun, Yuedi Yang, Jing Xu, Attaya Suvannasankha, Brian A. Walker, Pengyue Zhang   +6 more
wiley   +1 more source